Health-related quality of life (HRQoL) in AVAglio, a randomized, placebo (P)-controlled phase III study of bevacizumab (B), temozolomide (T) and radiotherapy (RI) in patients (pts) with newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Bottomley, A. [1 ]
Henrikkson, R. [2 ,3 ]
Taphoorn, M. J. B. [4 ,5 ]
Cloughesy, T. [6 ]
Wick, W. [7 ]
Mason, W. [8 ]
Saran, F. [9 ]
Nishikawa, R. [10 ]
Ravelo, A. [11 ]
Chinot, O. L. [12 ]
机构：
[1] EORTC, Qual Life Dept, Brussels, Belgium
[2] Reg Canc Ctr Stockholm, Stockholm, Sweden
[3] Umea Univ, Dept Radiotherapy & Oncol, Stockholm, Sweden
[4] Med Ctr Haaglanden Hague, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands
[6] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA
[7] Univ Med Ctr, Dept Neurooncol, Heidelberg, Germany
[8] Univ Toronto, Princess Margaret Hosp, Fac Med, Toronto, ON, Canada
[9] Royal Marsden NHS Fdn Trust, Neurooncol Unit, Sutton, Surrey, England
[10] Saitama Med Univ, Dept Neurooncol Neurosurg, Int Med Ctr, Saitama, Japan
[11] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[12] Aix Marseille Univ, CHU Timone, AP HM, Serv Neurooncol, Marseille, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3316
引用
收藏
页码：S780 / S780
页数：1
相关论文
共 50 条
  • [21] Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)
    Wefel, Jeffrey S.
    Armstrong, Terri S.
    Pugh, Stephanie L.
    Gilbert, Mark R.
    Wendland, Merideth M.
    Brachman, David G.
    Roof, Kevin S.
    Brown, Paul D.
    Crocker, Ian R.
    Robins, H. Ian
    Hunter, Grant
    Won, Minhee
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2021, 23 (07) : 1125 - 1138
  • [22] Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma
    Zhu, Jay-Jiguang
    Demireva, Petya
    Kanner, Andrew A.
    Pannullo, Susan
    Mehdorn, Maximilian
    Avgeropoulos, Nicholas
    Salmaggi, Andrea
    Silvani, Antonio
    Goldlust, Samuel
    David, Carlos
    Benouaich-Amiel, Alexandra
    Ram, Zvi
    JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (03) : 545 - 552
  • [23] Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma
    Jay-Jiguang Zhu
    Petya Demireva
    Andrew A. Kanner
    Susan Pannullo
    Maximilian Mehdorn
    Nicholas Avgeropoulos
    Andrea Salmaggi
    Antonio Silvani
    Samuel Goldlust
    Carlos David
    Alexandra Benouaich-Amiel
    Journal of Neuro-Oncology, 2017, 135 : 545 - 552
  • [24] HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH BEVACIZUMAB BEYOND PROGRESSION: A PROSPECTIVE TRIAL
    Tanaka, Shota
    Narita, Yoshitaka
    Mukasa, Akitake
    Nagane, Motoo
    Aoki, Tomokazu
    Wakabayashi, Toshihiko
    Uzuka, Takeo
    Nakamura, Hideo
    Arakawa, Yoshiki
    Suehiro, Satoshi
    Nakada, Mitsutoshi
    Morita, Satoshi
    Kato, Mamoru
    Ichimura, Kouichi
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2020, 22 : 176 - 176
  • [25] Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
    Sarkaria, Jann Nagina
    Ballman, Karla V.
    Kizilbash, Sani Haider
    Sulman, Erik P.
    Giannini, Caterina
    Mashru, Sandeep H.
    Piccioni, David Eric
    Friday, Bret Edward Buckley
    Dixon, Jesse G.
    Kabat, Brian
    Laack, Nadia N.
    Hu, Leland
    Kumthekar, Priya
    Ellingson, Benjamin M.
    Anderson, S. Keith
    Galanis, Evanthia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] An international phase III, randomised, controlled trial evaluating health-related quality of life in glioblastoma patients
    Taphoorn, MJB
    Stupp, R
    Osoba, D
    Curschmann, J
    Kortmann, R
    van den Bent, M
    Mason, W
    Coens, C
    Eisenhauer, E
    Bottomley, A
    NEURO-ONCOLOGY, 2004, 6 (04) : 358 - 358
  • [27] RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA
    Chinot, Olivier L.
    Wick, Wolfgang
    van den Bent, Martin J.
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Revil, Cedric
    Kerloeguen, Yannick
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2014, 16
  • [28] Health-related quality of life in patients with advanced metastatic melanoma: Results of a randomized phase III study comparing temozolomide with dacarbazine
    Kiebert, GM
    Jonas, DL
    Middleton, MR
    CANCER INVESTIGATION, 2003, 21 (06) : 821 - 829
  • [29] Health-related quality of life (HRQoL) in newly diagnosed patients (pts) with chronic phase chronic myelogenous leukemia (CP CML) treated with bosutinib (BOS) or imatinib (IM).
    Lipton, J. H.
    Trask, P. C.
    Cella, D.
    Duvillie, L.
    Powell, C.
    Ramanan, M. V.
    Maslyak, Z.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] HEALTH-RELATED QUALITY OF LIFE AND NEUROCOGNITIVE STATUS IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED ON A PHASE II TRIAL OF HYPOFRACTIONATED RADIOTHERAPY WITH TEMOZOLOMIDE
    Reddy, Krishna
    Gaspar, Laurie
    Kavanagh, Brian
    Waziri, Allen
    Chen, Changhu
    NEURO-ONCOLOGY, 2012, 14 : 158 - 159
12345